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Abstract
Background Enhanced recovery programmes improve outcomes in surgery, but their implementation after upper gastrointestinal
resection has been limited. The aim of this study was to compare short-term outcomes for patients undergoing oesophagogastric
surgery in an enhanced recovery programme (EROS).
Methods EROSwas developed after a multidisciplinary meeting bymultiple rounds of revision. EROSwas applied to all patients
undergoing major upper GI resection at a university teaching hospital in the UK from 20/9/13, with data reviewed at 18/09/15.
EROS was assessed to identify predictors for compliance.
Results One hundred six patients underwent major upper GI resection including 81 oesophagectomies, 24 gastrectomies and 1
colonic interposition graft. Major complications (Clavien Dindo ≥3) occurred in 12 patients with 1 in-hospital death. Thirty-five
patients (44%) were discharged on target day 8 of the EROS programme. Age and complications were independently associated
with missing this discharge target.
Conclusion Enhanced recovery is feasible and safe after major upper gastrointestinal surgery.
Keywords Enhanced recovery . Oesophageal surgery .
Surgery . Oesophagectomy . Gastrectomy
Introduction
Enhanced recovery after surgery (ERAS) programmes have
proven benefits in mortality and morbidity in a range of set-
tings. ERAS programmes reduce patient length of stay (LOS)
and reduce costs.1–3 The implementation of ERAS after upper
gastrointestinal surgery has been limited by a number of fac-
tors. These include the historically high levels of mortality and
morbidity after these types of operations and traditional surgi-
cal concerns regarding early feeding and anastomotic leak.
The evidence for ERAS in oesophageal surgery is poor; in a
recent systematic review, Findlay et al. identified only eight
retrospective series with a total of 1127 patients. These were
predominantly reports of single surgeon series and open
resections.4 In some units, one surgeon but not others have
embraced ERAS for oesophageal surgery5, and in other units,
only the fittest patients have been included, making the overall
benefits hard to establish.6
The use of minimally invasive oesophagectomy (MIO) is
gaining momentum in the UK with 43.2% of resections being
either totally minimally invasive or hybrid operations (laparo-
scopic abdomen and open chest) in the latest national audit.7
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To date, very few reports have included patients treated with
MIO within an enhanced recovery programme (ERP). The
most recent systematic review and pooled analysis of en-
hanced recovery after oesophagectomy identified 27 cases of
MIO in ERPs and 7 for MIO on conventional pathways.8
Therefore, the aims of this study were to develop, introduce
and analyse an enhanced recovery pathway for all patients
undergoing upper GI resection, including open, hybrid and
totally minimally invasive oesophagectomy.
Materials and Methods
Enhanced Recovery After Oesophagogastric Surgery
(EROS) Programme Development
The EROS programme was developed and implemented at
University Hospital Southampton (UHS) NHS Foundation
Trust, a single centre teaching hospital in the UK and a desig-
nated centre for oesophageal and gastric cancer surgery. A
draft EROS programme was proposed by the surgical team
and subjected to multidisciplinary professional review at a
dedicated EROS development day (25/01/2012). This event
was attended by Dr Donald Low (Virginia Mason Medical
Centre, Seattle), who provided detail of the well-established
programme at his centre, on which the UHS EROS pro-
gramme was based.9 Multiple rounds of protocol revision
were utilised to establish a programme that was considered
as best practice and applicable to patients being treated in
our centre by all key stakeholders (including surgeons,
anaesthetists, specialist nurses, ward nurses, physiotherapists,
occupational therapists, dieticians and patients (Supplemental
document 1)). The fundamental components of the pathway
involved pre, peri and post-operative elements including pa-
tient, carer and team expectation and education, preoperative
carbohydrate loading, optimised anaesthesia, fluid and pain
management, early and consistent mobilisation, timely remov-
al of tubes and drains, early oral intake without the routine use
of upper GI swallow studies and aggressive goal setting. Full
details of the programme, including daily goals can be found
in Supplemental document 2. The programme was initially
designed for all patients who underwent a primary operation
including oesophageal anastomosis (oesophagectomy or total
gastrectomy), but in practice was used for all patients who
underwent major surgery (including sub-total gastrectomy).
The programme also included a previously published risk pre-
diction tool for anastomotic leak and major complications
after oesophageal surgery.10 The target time for discharge
was set at post-operative day 8, with the goal of discharge to
the patient’s home or usual place of residence without any
increase in support. The EROS pathway was applied to all
patients undergoing major oesophageal and gastric resections
from 20/09/2013, with data presented up to 18/09/2015. There
were no a priori exclusion criteria. Patients with carcinoma of
the oesophagus or stomach were staged and considered for
neoadjuvant therapy based on established protocols and
underwent surgery as previously described.11
Outcome Measures
Data recorded included demographics, tumour characteristics,
type of resection, operative times (defined as knife-to-skin to
wound closure), estimated blood loss (calculated from suction
bottles and weighed swabs), critical care unit stay, overall
hospital stay (defined as day of surgery until day of discharge),
histopathologic analysis of the surgical specimen, morbidity
and mortality. TNM-7 was used to report tumour stage.
Pathologic tumour clearance (‘R’ status) was determined ac-
cording the Royal College of Pathologists system (>1 mm
clearance). Postoperative complications were graded accord-
ing to the Clavien–Dindo classification12 and were recorded
for the entire inpatient stay. Clavien–Dindo grades I and II
represent minor complications, whereas grades III and IV rep-
resent major complications (grade III requires radiologic en-
doscopic or surgical intervention; grade IV indicates life-
threatening complication requiring intensive care manage-
ment). An anastomotic leak (AL) was confirmed by radiology
(contrast-enhanced multi-detector CT scan or water-soluble
contrast studies), endoscopy or during surgical exploration.
Elements of EROS were recorded to provide a comprehensive
assessment of compliance covering all aspects of the enhanced
recovery programme.
Statistics
Statistical analysis was performed with SPSS® version 21
(SPSS, Chicago, Illinois, USA). A p value <0.05 was consid-
ered statistically significant.
Results
One hundred six consecutive patients underwent major upper
GI surgery and a detailed analysis of this cohort is presented in
Table 1, including oesophagectomies and gastrectomies
shown separately.
Demographics
Themedian age was 67 years with a male predominance (74%
male versus 26% female). Patients who underwent gastrecto-
my were older (median age 71 versus 66 years for
oesophagectomy). The majority of patients had adenocarcino-
ma of the oesophagus or gastro-oesophageal junction and lo-
cally advanced disease (T3 in 56%) with lymph node metas-
tasis (N1+ in 65%) on preoperative staging. Neoadjuvant
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therapy was used in 71% (chemotherapy in 49% and chemo-
radiotherapy in 24%).
Operative Outcomes
Operative outcomes for the whole cohort and specifically for
oesophagectomy and gastrectomy are presented in Table 2.
There were 3 conversions to open procedures, all in the MIO
group (n = 3/29 10%). The reasons for conversion were
abdominal adhesions in 1 patient and in 2 patients the anaesthe-
tist was unable to isolate the right lung at the beginning of the
thoracic stage. Five operations required additional procedures, 2
lung resections (1 concurrent lung lesion of unknown aetiology
and 1 concurrent primary lung cancer) and 3 splenectomy. Forty-
eight patients (45%) had a feeding jejunostomy placed.
A complete microscopic resection (R0) was achieved
in 94 patients (89%), with a median lymph node yield
of 24 (range 8–64).
Table 1 Patient, treatment and
tumour demographics Variable Whole cohort Oesophagectomy Gastrectomy
Number of patientsb 106 81 24
Median age (years)a 67 (26–87) 66 (40–82) 71 (26–81)
Sex ratio (M:F) 78:28 75:25 70:30
Pre-op median BMIa 27 (20–39) 27 (20–35) 26 (21–39)
ASA grade
I 10 (9) 8 (10) 2 (8)
II 70 (66) 55 (68) 15 (63)
III 25 (24) 17 (21) 7 (29)
IV 1 (1) 1 (1)
Neoadjuvant chemotherapy 49 (47) 35 (44) 14 (58)
Neoadjuvant chemoradiotherapy 25 (24) 25 (31)
Surgery only 31 (30) 20 (25) 10 (42)
ypT or pT
0 19 (18) 19 (24)
IS/HGD 4 (4) 4 (5)
1 12 (12) 9 (11) 3 (13)
2 9 (9) 8 (10) 1 (4)
3 47 (46) 38 (48) 9 (38)
4 12 (12) 2 (3) 10 (42)
ypN or pN
0 58 (56) 53 (66) 5 (21)
1 14 (14) 11 (14) 3 (13)
2 19 (18) 11 (14) 8 (33)
3 12 (12) 5 (6) 7 (29)
ypM or pM
0 96 (93) 76 (95) 20 (83)
1 7 (7) 4 (5) 3 (13)
Tumour type
Adenocarcinoma 80 (76) 58 (72) 22 (92)
Squamous cell carcinoma 18 (17) 18 (22)
Adenosquamous cell carcinoma 1 (1) 1 (1)
Dysplasia 2 (2) 2 (2)
Basaloid 1 (1) 1 (1)
Leiomyoma/GIST 1 (1) 1 (4)
Neuroendocrine 1 (1) 1 (1)
Benign ulcer 1 (1) 1 (4)
Values in parentheses are percentages unless indicated
a Values in parentheses are range
b Total cohort includes 1 colonic interposition
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Overall median length of stay was 9 days for all patients
(range 4–90 days) and was 9 days for patients following
oesophagectomy (range 6–90). All patients were discharged
home (or to their usual place of residence) with no increase in
the level of care provided except in 6 cases (5.6%) where
increased support was required. Of these 6 patients, 4 experi-
enced major complications and required readmission to inten-
sive care (Clavien–Dindo grade 4). These patients had some
of the longest lengths of stay. Of the other 2 patients, 1 had a
pre-existing below-knee amputation and required a short-term
increase in care and the other was an elderly man with no
family support who suffered a post-operative chest infection.
There was 1 in-hospital death (1%) at 59 days after a hybrid
oesophagectomy. The patient died from multi-organ failure,
after an anastomotic leak, having been treated preoperatively
with high-dose steroids for concurrent lymphoma. There were
three additional outpatient deaths: at 74 days after a hybrid
oesophagectomy from rapidly progressive recurrent disease
and at 88 and 89 days after palliative gastrectomy from disease
progression; (90-day mortality: 4%).
Major complications (Clavien–Dindo; CD 3–4) occurred
in 11 patients (11%). Anastomotic leak occurred in 5 patients
(5%) and chyle leak in 8 patients (8%). Five patients (5%)
required a return to theatre and 29 patients (27%) suffered
respiratory complications, which were minor (CD <3) in the
majority (20 patients). Fifteen patients (14%) were readmitted
within 30 days of discharge.
A detailed analysis for oesophagectomies only is presented
in Supplementary Tables 5 and 6.
EROS Pathway Compliance
Table 3 shows all major elements of the Southampton EROS
pathway assessed for compliance. The EROS pathway
Table 2 Operative and surgical
outcome data Variable Whole cohort Oesophagectomy Gastrectomy
Number of patients 106 81 24
Extra procedures 5 (5) 4 (6) 1 (4)
Feeding jejunostomy 48 (45) 46 (57) 1 (4)
Median duration of operation (min)a 329 (120–530) 340 (240–530) 210 (139–390)
Median blood loss (ml)a 250 (0–1892) 250 (0–1892) 150 (50–1400)
Median total length of stay (days)a 9 (4–90) 9 (6–90) 7 (4–31)
Median ITU staya 0 (0–31) 0 (0–31) 0 (0–24)
Median HDU staya 4 (0–13) 4 (0–13) 2 (0–4)
Conversions 3 (3) 3 (4) 0 (0)
Anastomotic leak 5 (5) 4 (5) 1 (4)
Chyle leak 8 (8) 7 (9) 1 (4)
Inpatient Clavien Dindo max grade
0 42 (40) 27 (34) 15 (63)
1 7 (7) 5 (6) 2 (9)
2 45 (43) 39 (48) 5 (21)
3 3 (3) 3 (4) 0 (0)
4 8 (8) 6 (7) 2 (9)
5 1 (1) 1 (1) 0 (0)
Return to theatre 5 (5) 4 (5) 1 (4)
Cardiac complication 18 (17) 16 (20) 1 (4)
Respiratory complication 29 (27) 26 (32) 3 (13)
30 day mortality 0 (0) 0 (0) 0 (0)
90 day mortality 4 (4) 2 (3) 2 (9)
Readmission within 30 days of discharge 15 (14) 14 (17) 1 (4)
Median nodal yielda 24 (8–64) 26 (8–65) 30 (13–57)
Resection clearance
R0 94 (89) 69 (85) 24 (100)
R1 (CRM) 12 (11) 12 (15) 0 (0)
R1 (Long) 0 (0) 0 (0) 0 (0)
Values in parentheses are percentages unless indicated
a Values in parentheses are range
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documentation was missing for 16 patients and 10 patients
were taken off the pathway due to major complications. The
target discharge date of 8 days after surgery was achieved in
44% of patients. In total 61% of patients achieved
mobilisation of at least 25 m on post-operative day (POD) 1,
including 30% of patients who achieved compliance with the
POD 1 target mobilisation of 2 × 25 m walks. Similar compli-
ance rates were observed for POD 2–5. Oral intake of fluids
was established on POD 4 in 60% of patients and pureed diet
was established by POD 6 in 59%. Nasogastric tubes were
removed in the majority on POD 2 (54%) and in no patients
was reinsertion required.
Predictors of Discharge by Postoperative Day 8
A binary logistic regression analysis identified increasing age
and post-operative complications as factors independently as-
sociated with missing the predefined target of discharge on
POD8 (Table 4). Other factors including operative approach,
perioperative outcomes, tumour stage, ASA grade and EROS
targets were not associated with this discharge target.
Pre-EROS Experience
In the calendar year preceding the start of EROS, 72 consec-
utive patients underwent major upper GI resections (51
oesophagectomies). The overall median length of stay was
11 days ( range 4 to 55 days ) and 10 days fo r
oesophagectomies (range 6 to 43 days). Major complications
occurred in 18% and there were 3 deaths.
Discussion
This study demonstrated that EROS could be applied to all
patients who underwent major upper GI surgery with good
outcomes. Enhanced recovery was safe and effective after
oesophageal surgery and delivered low levels of morbidity
and short lengths of stay.
These findings are in line with results from other surgical
disciplines. For instance, in colorectal surgery ERAS halves
morbidity and significantly reduces length of stay.13 Published
results for enhanced recovery after oesophageal surgery have
shownmoremodest improvements, possibly due to reluctance
by the clinical teams to progress patients quickly for fear of
significant, life-threatening complications. The findings of
this study support the application of enhanced recovery for
all upper GI patients undergoing major resection, with rela-
tively aggressive targets. No major differences in outcome
between different surgical approaches were observed, but the
study was not designed to explicitly address this question.
The development of the EROS programme took into ac-
count the infrastructure and resources of the institute where it
Table 3 Enhanced recovery after oesophagogastric surgery milestone
compliance data
Variable
Number of patients 106
Data analysed 80 (76)
Missing data 16 (15)
EROS discontinued 10 (9)
Patient and team expectations
Preoperative patient information 68 (85)
Predicted discharge date recorded 3 (4)
Admission day of surgery 60 (75)
Post-operative destination Ward:HDU:ITU 1:70:9
Discharged home by POD 8 35 (44)
Analgesia
PCA 79 (99)
Epidural 60 (75)
Mobilisation
Hill-Rom bed utilised 53 (71)
POD 1
2 walks 24 (30)
1 walk 25 (31)
4 h sat out 44 (56)
2 h sat out 14 (18)
POD 2
3 walks 11 (14)
2 walks 29 (36)
1 walk 17 (21)
6 h sat out 49 (62)
3 h sat out 4 (5)
POD 3
4 walks 13 (16)
3 walks 8 (10)
2 walks 29 (36)
1 walks 16 (20)
6 h sat out 49 (63)
3 h sat out 17 (22)
POD 4
5 walks 5 (6)
4 walks 6 (8)
3 walks 11 (14)
2 walks 26 (32)
1 walk 19 (24)
6 h sat out 50 (64)
3 h sat out 15 (19)
POD 5
6 walks 6 (8)
5 walks 1 (1)
4 walks 13 (16)
3 walks 12 (15)
2 walks 15 (19)
1 walk 8 (10)
6 h sat out 50 (68)
2 h sat out 8 (11)
Nutrition
Preoperative carbohydrate loading 65 (81)
Day 1 step 1 80 (100)
Day 2 step 2 43 (54)
Day 4 step 3 48 (60)
Day 6 step 4 47 (59)
Tubes and drains
TWOC day 4 53 (66)
NG out
Day 2 43 (54)
Day 3 24 (30)
Day 4 10 (13)
Day 5+ 3 (4)
Chest drains left removed by POD 4 54 (78)
Chest drains right removed by POD 4 39 (57)
Chest drains right removed by POD 5 45 (68)
Values in parentheses are percentages unless indicated
POD postoperative day
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was introduced, meaning that it may not be applicable to dif-
ferent hospitals and healthcare systems.14 This could also be
considered as a benefit of the programme, as EROS contains
the fundamental elements of enhanced recovery tailored to the
local environment. Other centres wishing to introduce en-
hanced recovery can be reassured that adapting existing
programmes for use in their own hospitals is possible and
leads to good outcomes. Our experience with EROS suggests
that the multidisciplinary team begin to see the programme as
the default pathway for all patients undergoing major surgery.
Anecdotally, mobilisation of all patients has improved and the
BSTEP^ system (supplementary document 1) introduced for
oral intake is now applied to all upper GI patients. This has the
advantage of removing variation for the junior medical and
nursing staff whose shift patterns change regularly.
The study had a number of strengths. The cohort was con-
sistent with contemporary clinical practice; the majority of
patients had locally invasive, node positive oesophageal ade-
nocarcinoma treated with neoadjuvant therapy. The surgeons
involved had significant experience with minimally invasive
oesophagectomy11 meaning that the applicability of the results
for MIO have not been biased by a Blearning-curve^ effect.
Morbidity data was comprehensively collected by a dedicated
data manager and is reported using a validated system.
Overall outcomes are satisfactory and comparable with
data from the UK National Oesophagogastric Cancer
Audit (NOGCA)7 and previously published series.9 An
improvement in overall length of stay was observed when
compared to the year preceding the introduction of the
programme (9 versus 11 days) and our previously pub-
lished comparison of open and minimally invasive
oesophagectomy (9 versus 12 days).11 However, it is im-
portant to note that the benefit for oesophagectomies
alone when comparing the EROS time period with the
preceding year was only 1 day (9 versus 10 days). A
potentially more clinically relevant improvement was ob-
served for gastrectomies (7 versus 11 days), but the
number of gastrectomies in the EROS cohort was modest
(n = 24).
Whilst in this study, we have made no attempt to provide a
detailed Bbefore and after^ analysis of EROS,major morbidity
of 10% compares favourably with our experience (18%) in the
year preceding the introduction of the programme and with
other published series of oesophagectomies performed both
on conventional care pathways and within ERPs.5, 9, 11
Reduced morbidity for patients in EROS confirms previous
reports from all branches of surgery and may represent the
major benefit of enhanced recovery. This is particularly im-
portant for oesophageal surgery that has witnessed a dramatic
reduction in mortality in recent years, but has struggled to
make in-roads into relatively high complications rates.7
A reduction in pulmonary complications has been reported as
a significant benefit of both enhanced recovery andMIO.15, 16 In
this series, respiratory complications were observed in 27% of
patients. This apparently high level of respiratory complications
is in keeping with patients treated on a conventional pathway
(29.1%)8 but includes patients with relativelyminor deviations to
the clinical course (Clavien–Dindo 1 and 2) in the vast majority.
When only major respiratory complications are considered, the
incidence falls to 6.6%.
Considerable concern exists within the surgical com-
munity regarding gastric conduit decompression and the
relevance of drainage procedures. No pyloroplasties or
other drainage procedures were performed in this series
and there were no instances of acute conduit distension. It
appears feasible and safe to remove nasogastric tubes and
recommence oral intake early in the post-operative course
(POD 2) without the routine use of upper GI swallow
studies.
We observed a significant number of readmissions within
30 days of discharge (14%). This may reflect an overly ambi-
tious policy of discharge, but is also related to an Bopen-door^
attitude towards discharged patients and the local geography
(the catchment area includes the Isle ofWight and the Channel
Table 4 Binary logistic regression analyses of factors affecting discharge by POD 8
Variables Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Patient
Age Quartile 1 (25.5–59 years) 1 Ref 1 Ref
Quartile 2 (59–66.5 years) 1.589 0.475–5.310 0.452 1.648 0.428–6.354 0.468
Quartile 3 (66.5–73 years) 1.901 0.564–6.410 0.300 2.007 0.507–7.942 0.321
Quartile 4 (73–87 years) 3.870 1.085–13.812 0.037 7.190 1.616–31.995 0.010
Post-operative
Maximum Clavien–Dindo inpatient complication No (0) 1 Ref
Minor (1–2) 4.050 1.708–9.602 0.001 5.257 1.774–15.575 0.003
Major (3–5) 19.800 2.324–168.661 0.006 28.381 2.946–273.370 0.004
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Islands). Our experience suggests that rather than being
viewed as a negative outcome, readmission should be expect-
ed in a relatively small proportion of patients as part of the
enhanced recovery programme. Further community support
for patients and their carers will be required to reduce
readmissions and will be a focus for pathway development.
Reporting of compliance data in ERPs is poor17 and
patients with complications are often removed from
ERPs. This makes it impossible to determine the efficacy
of different aspects of the ERP and their relative effects
on outcome.14 In an attempt to address this, compliance
with the major agreed components of EROS was docu-
mented and analysed. Age and complications defined by
the Clavien–Dindo classification were independently as-
sociated with missing the predefined discharge target of
8 days. These factors may not be surprising but offer
potential ways to improve the pathway. For example, pa-
tients of advanced age should be highlighted in the neo-
adjuvant or preoperative setting as potentially requiring
prehabilitation interventions or increased packages of care
to enable them to continue their rehabilitation, in the com-
munity. In addition, the focus should shift to preventing
minor as well as major complications and this will require
a whole multidisciplinary team approach.
In this study, compliance with target mobilisation was poor.
However, this probably reflects overambitious target setting.
The advantage of such target setting is that >60% of patients
walked >25 m on POD 1 and an improvement in mobilisation
quantity and distance was observed for each post-operative
day. Consistent mobilisations early in the post-operative
course proved labour intensive and difficult to achieve and
we may have overestimated the availability of local resources
to deliver this. Future efforts will be focussed on improving
compliance in this area and will depend upon the continued
development of the multidisciplinary team.
Conclusion
The experience described in this study with the introduction of
EROS demonstrates that enhanced recovery is feasible and
safe after major upper gastrointestinal surgery.
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